Synmosa Biopharma Corporation (TPEX:4114)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
New Drugs Segment	5.40B	4.96B	4.24B	3.15B	2.92B
New Drugs Segment Growth	8.78%	17.05%	34.70%	7.61%	15.46%
Pharmaceutical Ingredients Department	363.24M	325.78M	234.87M	119.57M	152.56M
Pharmaceutical Ingredients Department Growth	11.50%	38.71%	96.43%	-21.63%	-12.25%
Intersegment Income	-210.22M	-146.19M	-86.89M	-31.13M	-38.34M
Total	5.55B	5.14B	4.39B	3.23B	3.04B
Total Growth	7.96%	17.19%	35.59%	6.47%	13.37%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Taiwan	4.76B	4.45B	3.88B	2.81B	2.62B
Taiwan Growth	6.97%	14.83%	37.79%	7.43%	10.46%
China	564.55M	450.98M	271.73M	293.58M	301.67M
China Growth	25.18%	65.97%	-7.44%	-2.68%	72.46%
USA	2.21M	28.78M	62.74M	8.66M	-
USA Growth	-92.34%	-54.12%	624.84%	-	-
Canada	2.14M	15.50M	34.97M	30.29M	11.76M
Canada Growth	-86.16%	-55.68%	15.43%	157.61%	-
Thailand	29.70M	54.56M	39.60M	23.16M	25.88M
Thailand Growth	-45.56%	37.79%	70.99%	-10.52%	3.42%
Malaysia	34.36M	36.45M	30.75M	19.41M	19.09M
Malaysia Growth	-5.73%	18.54%	58.38%	1.67%	-23.39%
Singapore	75.89M	41.91M	-	-	-
Singapore Growth	81.06%	-	-	-	-
Other	79.11M	60.80M	70.10M	46.47M	60.99M
Other Growth	30.12%	-13.28%	50.85%	-23.80%	-27.50%
Total	5.55B	5.14B	4.39B	3.23B	3.04B
Total Growth	7.96%	17.19%	35.59%	6.47%	13.37%

Source: S&P Global Market Intelligence.